TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
November 30, 2023 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
November 27, 2023 07:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm ET to provide...
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing
November 08, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
November 07, 2023 16:05 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines
October 02, 2023 17:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in Upcoming Investor Conferences
September 28, 2023 16:29 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
August 23, 2023 07:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
August 17, 2023 16:01 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 15, 2023 06:05 ET
|
TFF Pharmaceuticals, Inc.
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected to extend cash runway through initial...